在抗pd-1/pd-l1作用下，通过直接阻断pd-1对cd8 t细胞的作用，并通过重新激活肿瘤特异性cd4 t细胞的辅助活性，促进cd8 t细胞的增殖。 手术治疗、放疗、化疗和免疫治疗是目前肿瘤治疗的4大手段。

2021年2月26日 · 本文说明肿瘤微环境中PD-1 + CD8 + T细胞相对于PD-1 + 调节性T 细胞（T reg ）的频率可预测程序性细胞死亡蛋白1（PD-1）阻断治疗的临床疗效，并且优于其他预测因子，包括程序性死亡配体1（PD-L1）表达或肿瘤突变负荷。本文通讯作者是日本名古屋大学医学部免疫学 …

2024年11月4日 · In vitro experiments reveal that PD-1 + CD8 + T cells can induce the pyroptosis of hepatocytes through elevated production of granzyme B and perforin-1. These results provide a novel explanation for the cytotoxic activity of pathogenic liver PD-1 + CD8 + T cells in autoimmune liver diseases and offer potential therapeutic targets.

2023年8月25日 · PD-1 + TCF-1 + stem-like CD8 T cells act as critical resource cells for maintaining T cell immunity in chronic viral infections and cancer. In addition, they provide the proliferative burst of effector CD8 T cells after programmed death protein 1 (PD-1)–directed immunotherapy.

In a murine HPV + HNC model, anti-PD-1 mAb therapy differentially modulated PD-1 high/low populations, and tumor rejection associated with loss of dysfunctional PD-1 high CD8 + T cells and a significant increase in PD-1 low TIL. Thus, the extent of PD-1 expression on CD8 + TIL provides a potential biomarker for anti-PD-1 based immunotherapy.

Our studies reveal a role for PD-1 as an integrator of CD8 + T cell signals that promotes CD8 + T cell memory formation and suggest PD-1 continues to fine-tune CD8 + T cells after they migrate into non-lymphoid tissues. These findings have important implications for PD-1-based immunotherapy, in which PD-1 inhibition may influence memory ...

2019年7月29日 · We show that PD-1 blockade in suboptimally primed CD8 + T cell conditions results in the generation of dysfunctional PD-1 + CD38 hi CD8 + cells 18, leading to resistance to anti-PD-1...

2024年8月28日 · PD-1 signaling inhibits the expression of Plpp1 through Akt-GATA1 pathway. The tumor microenvironment (TME) promotes metabolic reprogramming and dysfunction in immune cells. Here, we examined the impact of the TME …

2017年3月31日 · Conditional gene deletion showed a cell-intrinsic requirement of CD28 for CD8 T cell proliferation after PD-1 blockade. B7-costimulation was also necessary for effective PD-1 therapy in tumor-bearing mice. In addition, we found that CD8 T cells proliferating in blood after PD-1 therapy of lung cancer patients were predominantly CD28-positive.

2024年4月1日 · PD-1 + IL-2 combination therapy acts on PD-1 + TCF-1 + stem-like CD8 T cells among pools of LCMV-specific CD8 T cells, promoting their proliferation/differentiation, as seen during PD-1 monotherapy. The terminally differentiated CD8 T cell subset does not respond to PD-1 blockade, IL-2 monotherapy, or PD-1 + IL-2 combination therapy.